Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.

Authors

Shoshana Mehler

West Cancer Center, Memphis, TN

Shoshana Mehler , Seth Guilbeau , Shmuel Somer , Kevin Reed , Heather Greene , Daniel A. Vaena , Axel Grothey , Brad Somer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Translational Research, Tumor Biology, Biomarkers, and Pathology

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 542)

DOI

10.1200/JCO.2023.41.6_suppl.542

Abstract #

542

Poster Bd #

Abstract Disclosures

FEATURED

Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice.

Authors

Shoshana Mehler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Real-world ctDNA testing patterns, associated biomarkers and sites of metastasis in early stage colorectal cancer.

Poster

Sensitive detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes.

Poster

Non-invasive minimal residual disease detection of liver cancer using circulating tumor DNA features and α-fetoprotein: A prospective study.

Poster

Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort.